Shire PLC (LSE:SHP) - Share price - Overview

Stock Report

Shire PLC SHP

Last Price
GBX4,515.00

Day Change
-17.50|-0.39%

As of 20/09/2018
14:40:27 BST | GBX
Minimum 15 Minutes Delay.

Last Close4,532.50p
Day Range4,427.50 - 4,550.00
Mkt Cap35.55Bil
52-Wk Range2,940.50 - 4,576.00
Yield %0.00
ISINJE00B2QKY057
Volume748,410
P/E1,025.67
P/S2.72
P/CF9.67

Share Price

Total Returns 19/09/2018

 Chg (%)  
More ...
Shire PLC2.12 
FTSE 100 TR GBP-2.82
 
Financials
201520162017
More ...
Income Statement
Turnover6,416.7011,396.6015,160.60
Operating Profit1,542.501,951.703,397.20
Net Profit1,337.50603.504,253.50
Reported EPS2.260.774.66
Balance Sheet
Current Assets2,255.507,539.507,608.40
Non Current Assets14,354.3059,495.9060,148.50
Total Assets16,609.8067,035.4067,756.90
Current Liabilities3,706.107,743.307,882.00
Total Liabilities6,780.7038,087.4031,580.50
Total Equity9,829.1028,948.0036,176.40
Cash Flow
Operating Cash Flow2,337.002,658.904,256.70
Net Change in Cash-2,843.90392.50-63.50

Regulatory News

Director Dealings
TradedActionNotifierPriceAmountValue
More ...
29/06/2018PurchaseMr. Albert P L Stroucken56.2726114,686.00
29/06/2018PurchaseMr. Ian T. Clark56.2720711,647.00
29/06/2018PurchaseOlivier Bohuon4,298.931717,351.00
29/06/2018PurchaseMs. Sara Mathew56.2721912,322.00

Company Profile

Shire PLC is a biotechnology company focused mainly in the research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines for patients with rare diseases and other select conditions.

Sector

Biotechnology

Index

FTSE 100 ,FTSE 350 ,FTSE All Share ,FTSE Eurotop 100 ,FTSE Eurotop 300

Next Event 26/10/2018

Third Quarter Results
Ratios
Comp
More ...
PER (E)11.08
Div Yld (E)0.56
PEG (E)1.95
ROCE4.13
Op Mrgn0.22
EPS Grwth1.57
Dividends
PreviousLatest
More ...
Record Date09/03/1807/09/18
Ex-Div08/03/1806/09/18
Paid24/04/1819/10/18
Amnt21.464.26
Directors
More ...
Executive Director, Chief Financial OfficerMr Thomas Johannes Willi Dittrich
Non-Executive DirectorMr. Albert P L Stroucken
Executive Director, Chief Executive OfficerDr. Flemming Ornskov
Non-Executive DirectorMr. Dominic Blakemore
Non-Executive DirectorMr. William Burns
Non-Executive DirectorMs. Gail D Fosler
Non-Executive DirectorDr. David Ginsburg
Non-Executive DirectorMs. Anne Minto OBE
Non-Executive Director, ChairmanMs. Susan S Kilsby
Non-Executive DirectorMs. Sara Mathew
Non-Executive DirectorDr. Steven Gillis
Non-Executive DirectorMr. Ian T. Clark
Non-Executive DirectorOlivier Bohuon
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2018 Morningstar. All rights reserved.